Biotech sector looking to roar back this week and EXEL will lead the good mid-sized companies.
Just noticed Anonymous is on a bunch of other yahoo biotech boards pumping his short ETF... might work elsewhere, EXEL is the next ONYX...positive HCC data and we will be at 60$/share easy!! Put up a short position or shut up!!
Everyone please buy EXEL so Anonymous will shut up and try to cover his short position when this goes higher! 👍🏻
Can anyone tell me why this stick isnt $40 by now??? They are debt free and doing everything right and it just sits around $26-28!!! This is also a great buyout candidate. I just don't understand it..
Johnonymous, you leave me no choice. One more post from either you or yourself and mark my words I will blot out the sun on Monday leaving all of North America shrouded in darkness for about 2 hours!
Anyone knows how long FDA has to respond to the sNDA filed by EXEL today? Or there is no deadline at all? Thanks
EXEL is now retracing back to its 50 dma of 25.28. Once it breaches that level, it will then quickly drop to its 200 dma of 20.80. Sell everything and buy TZA......because this bubble is about to......POP
NDA submission for 1st line RCC! Timing is impeccable, considering the BMY results yesterday.
Very typical sell the news crowd is at work again. But you know how it end in the longer term -- say 3 days later? I now fully expect the PPS of EXEL to be above $30 mark before the next earnings. If there is positive data on HCC likely $35 before the earnings. Of course there is the possibility of good BO offer (which I personally dont prefer), or the market meltdown related to political upheaval.
Probably last best chance to cover under $27 shorties (consider it a gift)!
please someone tell me what is going on with exel dropping..?
Nasdaq has a paltry 28.50 PT on EXEL which indicates that the shares are currently fully valued. Buy TZA... because the selling will continue for the next few weeks.....🐻
Have that funny feeling in the bones that some NEWS is coming from EXEL very soon (and I don't mean BO news but rather data or FDA related)!
I see most people haven't figured it out yet.........Topline results released Tuesday from Bristol-Myers Squibb Co. (BMY) shows that the combination of two Bristol-Myers drugs, Opdivo and Yervoy, failed to show a statistically significant improvement over Pfizer's (PFE) Sutent in intermediate- and poor-risk kidney cancer patients. That's good news for Exelixis because previously released results already showed improvement from use of Cabometyx over Sutent in an identical sample of kidney cancer patients.
$30 next week
EXEL up AH. I suspect the BM Kidney trial failure (opdivo and Yuervoy combo) didn't beat sunitinib, has folks thinking that the path may be clearing for Cabo in this indication? Anyone else agree?
what happen? pulling back to red.
So John then why don't you short EXEL and let us all know that you did so we can come back to you in a few weeks/months and tell you how much you've lost. You know we're all long do you have the guts to admit that you're short and that your current short position is already way underwater. Time to cover bro and minimize your loss!
Double catalysts this am!! New FDA Filing and Big FLOP for BMY. CHEERS TO ALL LONGS!!🍻🍻
Why is this down with all the good news? This should be sky rocketing.